“Extremely fast-tracked”: Jacobs billion-dollar drugs factory wins international prize

A billion-dollar pharmaceutical factory designed and built by Dallas-headquartered Jacobs in Dublin has won the prize for project execution in the International Society for Pharmaceutical Engineering’s 2020 Facility of the Year Awards.

Jacobs provided architecture, engineering, construction management and turnover services for the state-of-the-art biopharmaceutical plant in Cruiserath, Dublin (pictured), for drugs company Bristol Myers Squibb.

Completed on budget and within the allotted 26 months, the 43,720-sq-m project was "extremely fast-tracked", judges noted.

The campus, which opened in 2017, was the largest ever capital investment for Bristol-Myers Squibb, and is its first biologics manufacturing facility in Europe, said Cruiserath Biologics general manager, Noel Heaney.

At peak construction the project was Europe’s biggest in the pharmaceutical sector, with more than 2,200 people on site.

  • See the factory being built:


Jacobs said it demanded advanced project delivery techniques and collaboration among its experts in Ireland, the US and India, who worked around the clock to meet the deadline.

The facility was also awarded LEED Silver certification for its sustainability performance in respect of design, construction and operation.

The project went from award of construction management in May 2015 to groundbreaking in August 2015 and first steel standing in early November.

Building occupancy was achieved for the Laboratory, Office, and Cafeteria (LOC) facility in September 2017, and for the Manufacturing Building in November 2017.

Koti Vadlamudi, Jacobs’ senior vice president for advanced facilities, said: "The project is a huge success for Jacobs, Bristol Myers Squibb, and ultimately the many patients that rely on these medicines produced in the Dublin campus."

Image: Bristol Myers Squibb’s new biologics manufacturing facility at Cruiserath, Dublin (Courtesy of Jacobs)

Story for GCR? Get in touch via email: [email protected]

Latest articles in News